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In Brief
Protein-restricted (PR) diets improve
metabolic health in mice. Fontana et al.
find that PR diets improve metabolic
health in humans and that a specific
reduction in the consumption of three
branched-chain amino acids (BCAAs)—
leucine, isoleucine, and valine—by mice
improves many aspects of glycemic
control and body composition to the
same extent as reducing all dietary amino
acids.
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Protein-restricted (PR), high-carbohydrate diets
improve metabolic health in rodents, yet the precise
dietary components that are responsible for these
effects have not been identified. Furthermore, the
applicability of these studies to humans is unclear.
Here, we demonstrate in a randomized controlled
trial that a moderate PR diet also improves markers
of metabolic health in humans. Intriguingly, we find
that feeding mice a diet specifically reduced in
branched-chain amino acids (BCAAs) is sufficient
to improve glucose tolerance and body composition
equivalently to a PR diet via metabolically distinct
pathways. Our results highlight a critical role for die-
tary quality at the level of amino acids in the mainte-
nance of metabolic health and suggest that diets
specifically reduced in BCAAs, or pharmacological
interventions in this pathway,may offer a translatable
way to achieve many of the metabolic benefits of a
PR diet.INTRODUCTION
A calorie-restricted (CR) diet, in which total caloric intake is
reduced while maintaining adequate nutrition, promotes meta-
bolic health and longevity in invertebrate model organisms and520 Cell Reports 16, 520–530, July 12, 2016 ª 2016 The Authors.
This is an open access article under the CC BY-NC-ND license (http://mammalian species ranging from mice to humans (Colman
et al., 2014; Fontana et al., 2010; Lamming and Anderson,
2014; Mercken et al., 2012). Mammals, including humans,
placed on a CR diet, significantly lose body weight and abdom-
inal fat and display a robust improvement in glycemic control and
insulin sensitivity (Barzilai et al., 1998; Foster et al., 2003; Weiss
et al., 2006). A CR diet usually involves decreased consumption
of all macronutrients, and the role of decreased protein, in
particular, has received significant attention (Fontana and Par-
tridge, 2015; Weindruch and Walford, 1988). Recently, protein-
restricted (PR) diets have been shown to significantly improve
the metabolic health and longevity of rodents (Ables et al.,
2014; Fontana and Partridge, 2015; Solon-Biet et al., 2014,
2015).
Although in humans, high-protein, low-carbohydrate diets have
recently been popular for weight loss, epidemiological studies
suggest that high-protein intake correlateswith increasedmortal-
ity, whereas lower protein intake is associated with decreased
mortality (Lagiou et al., 2007; Levine et al., 2014). Indeed, individ-
uals consuming high-protein diets are at increased risk of devel-
oping metabolic diseases including obesity and type 2 diabetes
(Halkjæret al., 2011;Sluijset al., 2010;Vergnaudetal., 2013). Little
is knownabout themolecularmechanisms throughwhichPR reg-
ulatesmetabolichealth.Moreover,manyof thestudiesconducted
thus far have utilizedextremely restrictiveproteindiets,well below
the estimated average requirement for human adults, and are
therefore likely unsustainable and unhealthy (Otten et al., 2006).
The impact of amoderate PR diet without CR onmetabolic health
in humans has not been considered.creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. A Naturally Sourced Low-Protein Diet Improves the Metabolic Health of Mice
(A and B) Glucose (A) and pyruvate (B) tolerance tests onmale C57BL/6Jmice fed a naturally sourced 21%or 7%protein diet for 3 or 5 weeks, respectively (n = 6–
9/group; Tukey-Kramer test following ANOVA, *p < 0.05). Error bars represent SE.
(C–E) Mice were fasted overnight and (C) blood glucose and (D) insulin weremeasured, and (E) the HOMA2-IR was calculated after 6 weeks on the specified diets
(n = 6–9/group; two-tailed t test, *p < 0.05, #p < 0.11). Error bars represent SE.
(F) Food consumption was measured after 2 weeks on the 21% or 7% protein diets (n = 6–9/group; two-tailed t test, *p < 0.05). Error bars represent SE.
(G) Weight was determined immediately prior to diet start and after 3 and 8 weeks (n = 6–9/group; two-tailed t test, *p < 0.05). Error bars represent SE.
See also Figure S1.Over the last decade, evidence has mounted that certain indi-
vidual amino acids (AAs), the building blocks of protein, have
distinct effects on metabolism (Brown-Borg et al., 2014; Ed-
wards et al., 2015; Grandison et al., 2009; Miller et al., 2005). In
particular, several studies have observed increased serum levels
of the three branched-chain amino acids (BCAAs)—leucine,
isoleucine, and valine—in insulin-resistant humans, and indeed
BCAA levels are predictive of development of type 2 diabetes
(Lynch and Adams, 2014). A possible causal role for BCAAs in
the pathogenesis of type 2 diabetes has been suggested, and
BCAA supplementation in the context of a high-fat diet promotes
the development of insulin resistance in rats (Newgard et al.,
2009). Studies using knockout diets—in which one AA is
completely removed from the diet—have found that elimination
of dietary leucine for 1 week improves glycemic control in mice
(Xiao et al., 2011, 2014).
In this study, we determined how a moderate PR diet impacts
the metabolic health of both humans and mice and tested the
hypothesis that these effects are mediated by decreased con-
sumption of BCAAs. We determined that moderate PR improves
multiple indicators of metabolic health in both humans andmice,
and specific dietary restriction of all three BCAAs, but not of
leucine alone, improves metabolic health, improving glucose
tolerance and reducing fat accumulation. Unexpectedly, weobserved negative effects of restricting dietary leucine alone
on dermal and visceral adiposity. Our data suggest a critical
role for dietary BCAAs in the regulation of metabolic health and
suggest that protein quality—the specific amino acid composi-
tion of the diet—plays an important role in the regulation of meta-
bolic health.
RESULTS
Moderate Protein Restriction Improves Metabolic
Health in Mice and Humans
We placed C57BL/6J wild-type mice on diets in which either
21% of calories or 7% of calories were derived from protein,
which we have previously used to explore the impact of moder-
ate PR on cancer (Fontana et al., 2013; Lamming et al., 2015).
Mice fed the 7% PR diet demonstrated improved glucose toler-
ance (Figure 1A), as well as decreased fasting blood glucose and
insulin levels and reduced HOMA2-IR values (Figures 1B–1D).
Mice fed the 7% PR diet also showed improved pyruvate toler-
ance and responded normally to insulin injection, indicating
improved suppression of gluconeogenesis (Figures 1E and
S1A). Despite consuming more food, mice on the 7% PR diet
gained less weight than mice on the 21% protein control diet
over the course of 2 months (Figures 1F and 1G). BodyCell Reports 16, 520–530, July 12, 2016 521
Table 1. A Human Clinical Trial of Protein Restriction: Physical Parameters
Protein-Restricted Within-Group (p) Control Within-Group (p) Among-Group (p)
Age (years) 52.46 ± 6.76 53.00 ± 7.71 0.82
BMI (kg/m2)
Baseline 30.66 ± 5.43 30.15 ± 5.84
Follow-up 29.90 ± 5.32 30.18 ± 5.67
D BMI 0.76 ± 0.75 <0.0001 0.03 ± 0.51 0.81 0.001
Weight (kg)
Baseline 101.46 ± 18.75 93.17 ± 17.25
Follow-up 98.84 ± 18.61 92.96 ± 16.87
D Weight 2.62 ± 2.18 <0.0001 0.21 ± 1.36 0.52 0.001
Fat mass (kg)
Baseline 33.24 ± 11.91 31.07 ± 11.83
Follow-up 31.86 ± 11.09 30.72 ± 11.45
D Fat mass 1.37 ± 1.55 0.001 0.36 ± 1.02 0.15 0.02
Humans were randomly assigned to a 7%–9%protein-restricted (PR) or control diet group (19male subjects per group), and physical parameters were
assessed at baseline and at a follow-up visit 43 ± 11 days later. Change (D) represents the difference between the baseline and follow-up visit. Changes
between and within the PR and control groups were tested with analysis of covariance and paired t tests. Statistical tests were two-tailed, with
significance accepted at p < 0.05. Errors represent SD.composition analysis suggested that while consumption of a
low-protein diet slowed the gain of lean mass, fat mass accumu-
lation was almost entirely blocked (Figures S1B and S1C). Mice
eating the 7% PR diet had no change in spontaneous activity,
but exhibited increased respiration throughout a 24-hr cycle
and had increased energy expenditure at night (Figure S2).
To determine the relevance of these results to humans, we
analyzed data from a randomized controlled trial (RCT) we
conducted to determine the health effects of PR without calorie
restriction in 38middle-aged overweight andmildly obese (base-
line BMI 30 kg/m2) human males. The 19 volunteers random-
ized to PR were fed customized isocaloric 7%–9% protein
diets for an average of 43 days, while the 19 control subjects
consumed their usual diets, consisting of 50% more protein
per day (Table S1). We measured physical parameters and
collected blood for metabolic analysis in patients after an over-
night fast, both at baseline and at a follow-up visit at the end of
the trial. As this was an RCT, some baseline parameters were ex-
pected to vary between the control and PR groups; our analysis
therefore focused on the changes within each diet group (within-
group p) and the differences between the changes seen in each
group (among-group p) (Tables 1 and 2).
Humans eating isocaloric PR diets, but not those in the control
group, showed very similar effects to mice placed on a PR diet,
with a significant decrease in body weight (2.6 kg), fat mass,
and BMI (Table 1). We also observed a significant decrease in
fasting blood glucose levels, although there was no effect of
PR on the level of insulin; however, we observed a doubling of
levels of the insulin-sensitizing hormone FGF21 in subjects fed
a PR diet, with no change in FGF21 levels in the control group
(Table 2); a similar increase in FGF21 was previously observed
in humans fed a more severe PR diet (Laeger et al., 2014a). We
also observed a significant decrease in plasma levels of the three
branched-chain amino acids (BCAAs)—leucine, isoleucine, and
valine—that are associated with insulin-resistance in humans522 Cell Reports 16, 520–530, July 12, 2016and rodents (Table 2) (Lynch and Adams, 2014; Newgard
et al., 2009). With the exception of lysine, we did not observe
decreased plasma levels of any of the other essential amino
acids in humans on a PR diet (Table S2).
Specific Reduction of Dietary Branched-Chain Amino
Acids Improves Glucose and Pyruvate Tolerance
In order to study the specific effects of reducing dietary levels
of the three BCAAs on metabolic health, we designed and
constructed an amino acid-defined Control diet modeled on
the 21% protein diet used in Figure 1 and in our recent study
(Lamming et al., 2015). We also examined two diets with
decreased levels of amino acids, in which either 7%or 5%of cal-
ories were derived from amino acids through a uniform reduction
of every amino acid in the Control diet. The Low AA diet therefore
is based on the 7% protein diet used in Figure 1, while the more
restricted extremely Low AA (ExLow AA) diet reflects the 5%
protein diets used in some recent studies (Laeger et al., 2014a;
Solon-Biet et al., 2014, 2015). All three amino acid-defined diets
are isocaloric with identical levels of dietary fat; the exact formu-
lations of these diets are provided in Table S3.
We first verified that PR (in naturally sourced diets) and amino
acid restriction (in our newly constructed synthetic diets) were
comparable interventions. Mice fed either the Low AA or ExLow
AA diets had improved glucose tolerance relative to mice fed the
Control diet (Figure 2A). Just as with naturally sourced PR diets,
mice fed the LowAA and ExLowAA diets had improved pyruvate
tolerance, and despite eating more, gained significantly less
weight and reduced gain of fat mass (Figures S2A–S2C). The
improved glucose and pyruvate tolerance of mice fed the Low
AA and ExLow AA diets persisted throughout the study (Figures
S2D and S2E). Notably, while mice fed the Low AA diet were able
to maintain their body weight over the course of 13 weeks, mice
fed the ExLow AA diet lost both weight and lean mass
(Figure S2C); we therefore proceeded to use the Low AA diet
Table 2. A Human Clinical Trial of Protein Restriction: Blood Parameters
Protein-Restricted Within-Group (p) Control Within-Group (p) Among-Group (p)
Glucose (mg/dl)
Baseline 112.95 ± 36.38 103.31 ± 16.00
Follow-up 105.95 ± 31.26 105.98 ± 20.46
D Glucose 7.00 ± 9.33 0.02 2.67 ± 8.50 0.23 0.01
Insulin (mU/ml)
Baseline 7.33 ± 5.29 6.79 ± 4.20
Follow-up 7.38 ± 5.15 7.32 ± 4.55
D Insulin 0.05 ± 2.45 0.94 0.53 ± 2.68 0.4 0.56
FGF21 (pg/ml)
Baseline 131.55 ± 101.62 231.08 ± 244.61
Follow-up 260.33 ± 172.67 223.43 ± 143.76
D FGF21 128.78 ± 155.25 0.003 7.64 ± 176.06 0.86 0.02
Leucine (mmol/l)
Baseline 132 0.02 ± 13.62 132.42 ± 20.89
Follow-up 116.21 ± 21.87 136.41 ± 27.26
D Leucine 15.81 ± 21.03 0.004 3.99 ± 18.86 0.37 0.004
Isoleucine (mmol/l)
Baseline 66.43 ± 10.01 64.97 ± 11.28
Follow-up 60.29 ± 13.57 70.06 ± 15.07
D Isoleucine 6.14 ± 13.22 0.06 2.08 ± 11.01 0.42 0.04
Valine (mmol/l)
Baseline 237.82 ± 29.50 244.37 ± 42.29
Follow-up 193.18 ± 40.36 244.58 ± 47.90
D Valine 44.64 ± 42.72 <0.0001 0.21 ± 31.24 0.98 0.001
Humans were randomly assigned to a 7%–9% protein-restricted (PR) or control diet group (19 male subjects per group), and fasting blood levels of
glucose, insulin, FGF21, and the indicated amino acids were assessed at baseline and at a follow-up visit 43 ± 11 days later. Change (D) represents the
difference between the baseline and follow-up visit. Changes between and within the PR and control groups were tested with analysis of covariance
and paired t tests. Statistical tests were two-tailed, with significance accepted at p < 0.05. Errors represent SD.(7% of calories derived from amino acids) as a sustainable base-
line for investigation of the specific contribution of reduced die-
tary BCAAs.
We proceeded to design two additional diets: a Low Leu diet in
which the level of leucine was reduced by two-thirds to match
the level of the Low AA diet, while all other amino acids were
kept at the level of the a Control diet; and a Low BCAA diet in
which all three BCAAs were reduced by two-thirds to match
the levels of the Low AA diet, while all other amino acids were
kept at the level of the a Control diet. As with the Low AA diet,
all of these diets were isocaloric with the Control diet and had
identical levels of dietary fat; the exact formulations of these di-
ets are provided in Table S3. Mice fed either the Low Leu, Low
BCAA, or Low AA diets for 3 weeks had significantly improved
glucose tolerance compared to mice fed the Control diet
(Figure 2B).
We repeated the glucose tolerance test with a new group of
mice, comparing the Control and Low AA diets to a Low BCAA
diet and a new diet (Low FHKMTW) in which the other six essen-
tial amino acids (phenylalanine, threonine, tryptophan, methio-
nine, lysine, and histidine) were reduced by two-thirds to match
the levels of the Low AA diet; the levels of the non-essential
amino acids were increased in the LowBCAA and Low FHKMTWdiets to match the caloric contribution from amino acids, carbo-
hydrates, and fats to the Control diet (the exact formulations of
these diets are provided in Table S3). Mice fed the Low BCAA
or Low AA diets for 3 weeks again showed improved glucose
tolerance, but mice fed the Low FHKMTW diet showed no
improvement in glucose tolerance (Figure 2C).
Mice fed either the Low BCAA or Low AA diet also had
improved pyruvate tolerance but responded normally to insulin
injection, indicating improved suppression of gluconeogenesis
(Figures 2D and S3A). As seen in mice fed a Low AA diet (Figures
S2D and S2E), the improved glucose and pyruvate tolerance in
mice fed a Low BCAA diet persisted for the duration of the study
(Figures S3B and S3C). We collected blood from mice after an
overnight fast for the determination of blood glucose and insulin
levels.We observed decreased fasting blood glucose inmice fed
the Low BCAA and Low AA diets; neither diet decreased fasting
insulin levels or reduced HOMA2-IR values (Figures 2E–2G).
In combination, our results suggested that mice fed either a
Low AA or Low BCAA diet might have altered hepatic gluconeo-
genesis. We examined the expression of the gluconeogenic
genes glucose 6-phosphatase (G6p) and phosphoenolpyruvate
carboxykinase (PEPCK), as well as the expression of glucoki-
nase (Gck) in the livers of mice following an overnight fast. WeCell Reports 16, 520–530, July 12, 2016 523
AC
E F G H I
D
B
G6p
Figure 2. Reduced Consumption of BCAAs Improves Glycemic Control
(A) Glucose tolerance test (GTT) on male C57BL/6J mice fed either an amino acid-defined Control diet, or one of two diets (Low AA and ExLow AA) with reduced
amino acid content for 3 weeks (n = 9 mice/group; for GTT, Dunnett’s test following ANOVA, a = p < 0.05 Control versus Low AA, b = p < 0.05 Control versus
ExLow AA; for AUC, Dunnett’s test following ANOVA, *p < 0.05).
(B) GTT onmale C57BL/6J mice fed a Control diet, a Low AA diet, or a diet in which either leucine (Low Leu) or all BCAAs (Low BCAA) is reduced by two-thirds for
3 weeks (n = 8–12 per group; for GTT, Dunnett’s test following ANOVA, a = p < 0.05 Control versus Low AA, b = p < 0.05 Control versus Low BCAA, c = p < 0.05
Control versus Low Leu; for AUC, Dunnett’s test following ANOVA, *p < 0.05, **p < 0.01).
(C) GTT on male C57BL/6J mice fed a Control diet, a Low AA diet, a Low BCAA diet, or a Low FHKMTW diet in which six essential amino acids (F, H, K, M, T, and
W) are reduced by two-thirds, for 3 weeks (n = 8 per group; for GTT, Dunnett’s test following ANOVA, a = p < 0.05 Control versus Low AA, b = p < 0.05 Control
versus Low BCAA, c = p < 0.05 Control versus Low FHKMTW; for AUC, Dunnett’s test following ANOVA, **p < 0.01).
(D) Pyruvate tolerance test (PTT) on male C57BL/6J mice fed the indicated diets for 5 weeks (n = 8–12 per group; for PTT, Dunnett’s test following ANOVA,
a = p < 0.05 Control versus Low AA (7%), b = p < 0.05 Control versus Low BCAA, c = p < 0.05 Control versus Low Leu; for AUC, Dunnett’s test following ANOVA,
*p < 0.05).
(E–G) Mice were fasted overnight and (E) blood glucose and (F) insulin were measured, and (G) the HOMA2-IR was calculated after 7 weeks on the specified diets
(n = 8–12 mice/group; Dunnett’s test following ANOVA, *p < 0.05, #p < 0.065).
(H and I) Gene expression in the liver ofmice fasted overnight after 11weeks of feeding the indicated diets was determined by qPCR (n = 5–6/group, Dunnett’s test
following ANOVA, *p < 0.05 versus control; for grouped analysis, n = 6–18/group, two-tailed t test, *p < 0.05). Error bars represent SE.
See also Figures S2–S4.observed a strong induction of G6p in mice fed either a Low AA
or Low BCAA diet; however, PEPCK was not induced by any
diet, but was indeed was downregulated by Low AA, Low
BCAA and Low Leu diets, and Gck expression was decreased524 Cell Reports 16, 520–530, July 12, 2016only in mice fed a Low AA diet (Figure 2H). We also examined
the expression of pyruvate carboxylase (Pcx) and malic enzyme
1 (Me1), which are involved in themaintenance of pyruvate levels
and function upstream of PEPCK during gluconeogenesis
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B Figure 3. Ex Vivo Analysis of Pancreatic Islet
and b Cell Function
(A and B) An ex vivo insulin secretion assay was
performed to assess (A) insulin secretion per islet
and (B) islet insulin content in response to low
(1.7 mM) and high (16.7 mM) glucose in mice fed
either Control, Low AA, or Low BCAA diets for
11 weeks (n = 6 mice/group, Dunnett’s test
following ANOVA, *p < 0.05 versus Control).
(C–E) The impact of decreased BCAAs or total AAs
on ATP/ADP and Ca2+ oscillations of pancreatic
b cells was determined by simultaneous imaging
after 17 weeks of feeding the indicated diets (C),
and (D) plateau fraction and (E) amplitude was then
calculated (n = 149–176 islets; Dunnett’s test
following ANOVA). Error bars represent SE.(Merritt et al., 2011); the expression of both genes was strongly
decreased by all three diets (Figure 2I).
Reduction in Dietary Branched-Chain Amino Acids
Reduces b Cell Metabolic Stress
Next, we examined the effect of Low BCAA and Low AA diets on
pancreatic b cell function. We isolated pancreatic islets from
mice on the Control, LowBCAA, and LowAAdiets and examined
ex vivo glucose stimulated insulin secretion as well as the meta-
bolic and Ca2+ oscillations that drive secretion (Merrins et al.,
2013, 2016; Truchan et al., 2015). Islets isolated from the mice
fed Low BCAA and Low AA diets secreted significantly less insu-
lin per islet than islets from the mice fed Control diet (Figure 3A),
while the islet insulin content was also decreased by both diets,
significantly in the case of the Low AA diet (Figure 3B). By com-
parison with the Control diet, Low BCAA and Low AA diets
reduced the plateau fraction (a measure of the time the islet
spends in the active state) (Merrins et al., 2016; Nunemaker
et al., 2006) of both ATP/ADP and Ca2+ oscillations (Figures 3C
and 3D), reflecting decreased metabolic flux, a highly advanta-
geous state as unchecked b cell metabolic workload can lead
to b cell failure over time (Porat et al., 2011). Ca2+ oscillationCamplitude was increased in these cases
(Figures 3C and 3E), an efficiency that ex-
plains how the islets maintained adequate
secretion on the Low BCAA and Low AA
diets without the need for a higher meta-
bolic rate. These data indicate that b cell
glucose sensitivity is reduced in mice fed
either the Low BCAA diet or the Low AA
diet, an effect that is most likely due to
reduced insulin demand on the pancreatic
b cells of these mice rather than a primary
b cell lesion as both diets improved
glucose tolerance.
Reduced Dietary Leucine
Stimulates White Adipose Tissue
Mass
As with mice fed a Low AA or PR diet,
mice fed a Low BCAA diet consumemore food (Figure 4A). Despite consuming more calories, mice
fed either a Low BCAA or Low AA diet gained less weight over
the course of 10 weeks, with reduced gain of both fat mass
and lean mass (Figure 4B). In contrast, mice fed a Low Leu diet
did not eat more than Control diet mice (Figure 4A), and while
not statistically different from Control mice with respect to
weight, we observed that mice fed a Low Leu diet showed a
trend toward increased adipose mass and decreased lean
mass (Figure 4B); further, the mice appeared fatty upon nec-
ropsy. To quantify this, we collected skin (including dermal white
adipose tissue [dWAT]) (Alexander et al., 2015; Driskell et al.,
2014) from mice fed each diet, as well as the epididymal and
inguinal fat pads. All three adipocyte depots were assessed,
since these depots can be independently regulated. We
observed an 70% increase in the thickness of the dWAT from
mice fed a Low Leu diet (Figures 4C and 4D), with an 80% in-
crease in the weight of the epididymal fat pads (Figure 4E).
Reduction in Dietary BCAAs Is Metabolically Distinct
from Restriction of All Dietary AAs
Many of the metabolic effects of PR diet, including increased en-
ergy expenditure, are proposed to be mediated by the insulinell Reports 16, 520–530, July 12, 2016 525
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Figure 4. Dietary Branched-Chain Amino Acids Regulate Food Intake, Body Composition, and Adipose Mass
(A) Food consumption after 3 weeks on diets (n = 9 mice/group, means with the same letter are not significantly different from each other; Tukey-Kramer test
following ANOVA, p < 0.05).
(B) Weight and body composition were measured immediately prior to diet start and after 3 and 10 weeks on the indicated diets (n = 7–12/group, means with the
same letter are not significantly different from each other; Tukey-Kramer test following ANOVA, p < 0.05).
(C and D) Paraffin-embedded skin samples were collected after feeding mice the indicated diets for 11 weeks, sectioned, H&E stained (C) and the thickness of
dermal white adipose tissue (dWAT) was quantified (D) for non-anagen stage skin samples, measuring frommuscle to dermis. Scale bar, 100 mM (n = 5–11/group,
means with the same letter are not significantly different from each other; Tukey-Kramer test following ANOVA, p < 0.05).
(E) The epididymal white adipose tissue (eWAT) and inguinal white adipose tissue (iWAT) was collected at necropsy and weighed (n = 6–9/group, means with the
same letter are not significantly different from each other; Tukey-Kramer test following ANOVA, p < 0.05). Error bars represent SE.sensitizing hormone FGF21. FGF21 is induced in rodents and
humans fed an extremely restrictive protein diet (Laeger et al.,
2014a), andwe have found that FGF21 is also induced in humans
eating a moderate PR diet (Table 1). We thus examined levels of
FGF21 in mice fed a Control, Low AA, Low BCAA, or Low Leu
diet. Surprisingly, we found that while a Low AA diet increases
plasma FGF21 and induces FGF21 mRNA in both liver and skel-
etal muscle, we observed no increase in mice fed either a Low
BCAA or Low Leu diet (Figures 5A and 5B). In concordance
with this result, we observed increased nighttime energy expen-
diture only in mice fed a Low AA diet (Figure 5C). Further, FGF21
stimulates the production of adiponectin (Lin et al., 2013), andwe
observed increased plasma adiponectin only in mice fed a Low
AA diet (Figure 5D). Transcription of Fgf21 is mediated by
Pgc1a (Cornu et al., 2014), and indeed we observed increased
hepatic Ppargc1a expression only in mice fed a Low AA diet
(Figure 5E).
DISCUSSION
Understanding how dietary choices impact metabolic health is
an area of significant research interest, but until recently this
has largely focused on one’s choice of foods—e.g., caloric
intake of foods or choosing between vegetable, fish, and red
meat as a protein source. Recently, diets with altered macronu-526 Cell Reports 16, 520–530, July 12, 2016trient ratios have received significant attention from the public as
a potential means to combat obesity, while evidence suggesting
that a lower protein intake is positively associated with increased
health, survival, and insulin sensitivity has continued to mount
(Levine et al., 2014; Solon-Biet et al., 2014, 2015). However, an
understanding of the specific dietary components altered in a
low-protein diet that promote metabolic health has been lacking,
and it has been unclear if humans will receive immediate benefits
to metabolic health.
Here, we demonstrate that a moderate reduction in total die-
tary protein or selected amino acids can rapidly improve meta-
bolic health in both humans and mice. Reduction of dietary pro-
tein or total amino acids decreases fasting blood glucose levels
and improves glucose tolerance in both species in less than six
weeks, while also decreasing BMI and fat mass in humans and
decreasing weight and fat mass gain in young growing mice. A
moderate reduction of total dietary protein/amino acids in-
creases circulating FGF21 in both species just as efficiently as
more severe forms of protein restriction (Laeger et al., 2014a).
Importantly, we have now found that altered dietary quality—
the precise amino acid composition of the diet—regulates meta-
bolic health. Specifically, reducing the three branched-chain
amino acids (leucine, isoleucine, and valine) to the same level
as found in a low-protein diet is sufficient to improve many as-
pects of metabolic health, including glucose tolerance and
AD E
B C
Figure 5. The Effects of Reduced Branched-Chain Amino Acids Are Independent of FGF21
(A) FGF21 was measured in the plasma of mice fed the indicated diets for 17 weeks and sacrificed following an overnight fast (n = 8–9/group, Dunnett’s test
following ANOVA, *p < 0.05).
(B) Fgf21 expression in the liver, skeletal muscle, and adipose tissue of mice fasted overnight after 11 weeks of feeding the indicated diets was determined by
qPCR (n = 5–11/group, Dunnett’s test following ANOVA, *p < 0.05).
(C) Energy expenditure was measured after 4–6 weeks of feeding the indicated diets (n = 5–9/group, Dunnett’s test following ANOVA, *p < 0.05).
(D) Adiponectin was measured in the plasma of mice fed the indicated diets following an overnight fast after 17 weeks of diet feeding (n = 5–9/group, Dunnett’s
test following ANOVA, *p < 0.05).
(E) Ppargc1a expression in the liver of mice fasted overnight after 11 weeks of feeding the indicated diets was determined by qPCR (n = 5–6/group, Dunnett’s test
following ANOVA, *p < 0.05 versus control). Error bars represent SE.body composition, as effectively as a two-thirds reduction
in total consumption of dietary amino acids. The three BCAAs
contribute uniquely to the overall effect of dietary protein restric-
tion on glucose tolerance, as a two-thirds reduction in the other
six essential amino acids is not sufficient to improve glucose
tolerance (Figure 2C). This also clearly demonstrates that the ef-
fect of BCAAs on glucose homeostasis is independent from
changes in body composition, as diets reduced in either the
three BCAAs or the other six essential amino acids have similar
impacts on body composition (Figure S4). However, not all of
the effects of a low-protein diet are attributable to reduced
BCAAs; a specific reduction in dietary BCAAs does not induce
hepatic Ppargc1a, increase circulating FGF21 and adiponectin,
increase energy expenditure, or decrease hepatic Gck, effects
we observe exclusively in mice fed a Low AA diet (Figures 2
and 5). It remains to be determined if these other effects are
attributable to a reduction in total amino acids, the greater
impact of a Low AA diet on body composition, or if other specific
amino acids are responsible; for instance, recent research sug-
gests that methionine restriction is sufficient to induce FGF21
(Lees et al., 2014).
Notably, while some recent studies have suggested that a
low-protein diet improves metabolic health due to a high carbo-
hydrate to low protein ratio (Solon-Biet et al., 2014, 2015), we
have determined that reduced dietary BCAAs improves meta-
bolic health even in the absence of significant alterations in thedietary carbohydrate:protein ratio. An interesting question left
unanswered by our work is if a Low BCAA diet is (like a low-pro-
tein diet) most efficacious at promoting metabolic health when
accompanied by elevated dietary carbohydrates. Other signifi-
cant unanswered questions also remain, including the role of
other essential amino acids in the response to a moderate PR
diet and understanding the full biochemical basis for the effect
of reduced dietary BCAAs on hepatic gluconeogenesis. We
also observed several other significant physiological effects
that are ripe for future exploration, including alterations in
pancreatic b cell metabolism and body composition. Notably,
mice on the Low AA and Low BCAA diets ate significantly
more than mice on the Control diet, yet gained less weight. In
mice placed on a Low AA diet, this may be explained in part by
an FGF21-mediated increase in energy expenditure (Laeger
et al., 2014a), but mice eating a diet specifically reduced in the
BCAAs do not have increased FGF21 or increased energy
expenditure; the mechanism for this remains to be determined.
Interestingly, a recent study in Sprague-Dawley rats determined
that diets with reduced dietary BCAAs do not stimulate hyper-
phagia (Laeger et al., 2014b); whether this reflects differences
between mice and rats, or experimental differences in the length
of diet feeding and the degree of BCAA restriction remains to be
determined.
While we determined that mice fed a diet specifically reduced
in leucine did not eat more than control mice, we observed aCell Reports 16, 520–530, July 12, 2016 527
dramatic effect of leucine reduction on white adipose tissue
mass and distribution. In addition to increased visceral adipose
tissue, which is associated with poor metabolic health (Bergman
et al., 2006), we observed increased intradermal adipose tissue,
which has been proposed to be key to thermal insulation (Can-
non and Nedergaard, 2011; Kasza et al., 2014). Thus, thicker
dWAT could potentially decrease the energy required for ther-
mogenesis. As we did not observe increased dWAT or eWAT
in mice restricted in all three BCAAs, it is plausible that the phe-
notypes we observed could result from an imbalance between
the levels of leucine and either isoleucine or valine; both of these
amino acids have been implicated in lipid and fatty acid meta-
bolism (Du et al., 2012; Jang et al., 2016). However, the ultimate
molecular mechanism that drives the effect of a leucine reduced
diet on white adipose tissue is as yet unknown. If altered dietary
levels of a single amino acid can also regulate adipose mass in
humans, it suggests that the obesity epidemic sweeping the
world could be impacted by relatively subtle changes in dietary
quality at the level of amino acid composition.
Our findings highlight an important new avenue of investiga-
tion—specifically, how dietary quality at the level of individual
amino acids, not simply the quantity of food consumed, regu-
lates metabolic health. Our findings may be highly translatable
to the clinic through the use of diet plans or through the prescrip-
tion of already FDA-approved medical foods lacking specific
branched-chain amino acids. Our human clinical trial data sug-
gests that even a quite modest PR regimen may have significant
clinical benefits. In the long term, further investigation of the
molecular mechanisms and biological pathways regulated by
specific dietary amino acids may permit the development of
pharmacological agents to target these pathways to promote
metabolic health and to combat obesity and diabetes.EXPERIMENTAL PROCEDURES
For detailed procedure and reagents, see the Supplemental Experimental
Procedures.
Animals and Treatments
MaleC57BL/6Jmicewere purchased fromThe Jackson Laboratory at 8weeks
of age, and diet changes occurred at 9 weeks of age. Glucose, insulin, and
pyruvate tolerance tests were performed by fasting the mice overnight for
16 hr and then injecting either glucose (1 g/kg), insulin (0.75 U/kg), or pyruvate
(2 g/kg) intraperitoneally. Glucose measurements were taken using a Bayer
Contour blood glucose meter and test strips. Animal diets were obtained
from Envigo (formerly Harlan Laboratories). Natural sourced diets used were
21% protein (TD.10193) and 7% protein (TD.10192). Amino acid-defined diet
compositions and item numbers are provided in Table S3. Diets were adjusted
such that the 7% amino acid diet had a proportional, two-thirds reduction in all
amino acids, the branched-chain amino acid diet had a two-thirds reduction in
leucine, isoleucine, and valine, and the leucine diet had a two-thirds reduction
in only leucine. Mouse body composition was determined using an EchoMRI
3-in-1 Body Composition Analyzer according to the manufacturer’s proce-
dures. For assay of multiple metabolic parameters (O2, CO2, food consump-
tion) and activity tracking, mice were acclimated to housing in a Columbus
Instruments Oxymax/CLAMS metabolic chamber system for 24 hr, and
data from a continuous 24-hr period was then recorded and analyzed. All
mice were sacrificed between 8 a.m. and 12 p.m. after an 16 hr fast. Plasma
was prepared for analysis and stored at80Cuntil needed; tissues formolec-
ular analysis were flash-frozen in liquid nitrogen and prepared as described
below. Samples of skin were isolated from the belly of mice on the indicated528 Cell Reports 16, 520–530, July 12, 2016diets, and sections were paraformaldehyde-fixed (4%) overnight and then
paraffin-embedded for evaluation.
Human Clinical Trial
Subjects-experimental design and report were prepared following the
CONSORT standards for randomized clinical trials (clinicaltrials.gov identifier
NCT01692587). Male volunteers were recruited under a protocol approved
by the Institutional Review Board (IRB) (201011804) of the Washington Univer-
sity in St. Louis. Full details of this academic, single-center, parallel-group,
prospective, randomized, open-label, blinded endpoint (PROBE) trial and PR
diet are provided in the Supplemental Experimental Procedures.
qPCR
Total liver RNA was extracted with an RNeasy Mini Kit (QIAGEN) according to
the manufacturer’s instructions, or with Trireagent (Sigma). The concentration
and purity of RNA were determined by absorbance at 260/280 nm, and 1 mg
of RNA was used to generate cDNA (Superscript III; Invitrogen). Oligo dT
primers and primers for real-time PCR were obtained from Integrated DNA
Technologies. Reactions were run on an Applied Biosystems StepOne Plus
machine (Applied Biosystems) with Sybr Green PCR Master Mix (Invitrogen).
Actin was used to normalize the results from gene-specific reactions. Primer
sequences are given in Table S4.
Statistics
Statistical analysis was conducted using Prism 6 (GraphPad Software).
Glucose, insulin, and pyruvate tolerance tests were analyzed with two-way
repeated-measures ANOVA, followed by a Tukey-Kramer or Dunnett’s post
hoc test as appropriate. All other comparisons of three or more means were
analyzed by one-way ANOVA followed by a Dunnett’s or Tukey-Kramer post
hoc test as appropriate unless otherwise noted.
Islet Isolation and Ex Vivo Studies
Islets were isolated as previously described (Neuman et al., 2014). Full details
of the ex vivo glucose stimulated insulin secretion (GSIS) assay and metabolic
imaging are provided in the Supplemental Experimental Procedures.
Study Approval
Procedures involving animals were approved by the Institutional Animal Care
and Use Committees of the University of Wisconsin-Madison and the William
S. Middleton Memorial Veterans Hospital (Madison, WI). Procedures involving
human subjects were recruited under a protocol approved by the Institutional
Review Board of the Washington University in St. Louis, and patients provided
written informed consent prior to inclusion in the study.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.05.092.
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